Hypothesis: TREM2 lipid handling modulates microglial lysosomal stress in early AD.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["Amyloid-beta accumulation"]
B["TREM2 activation"]
C["SYK pathway engagement"]
D["Microglial lipid handling"]
E["Lysosomal stress response"]
F["Microglial activation state"]
G["Alzheimer's disease progression"]
A --> B
B --> C
B --> D
D --> E
C --> F
E --> F
F --> G
A["Amyloid-beta accumulation"]:::red
B["TREM2 activation"]:::blue
C["SYK pathway engagement"]:::blue
D["Microglial lipid handling"]:::blue
E["Lysosomal stress response"]:::red
F["Microglial activation state"]:::blue
G["Alzheimer's disease progression"]:::red
classDef red fill:#ef5350,stroke:#b71c1c,color:#ffffff
classDef blue fill:#4fc3f7,stroke:#0277bd,color:#000000
classDef green fill:#81c784,stroke:#2e7d32,color:#000000
classDef yellow fill:#ffd54f,stroke:#f9a825,color:#000000
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
5 citations5 with PMID5 mediumValidation: 0%5 supporting / 0 opposing
✓For(5)
5
No opposing evidence
(0)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
2
MECH 3CLIN 0GENE 2EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
TREM2 drives microglia response to amyloid-β via S…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.
IF TREM2 lipid-sensing function is pharmacologically enhanced using an agonistic antibody (e.g., AL002c) in 5xFAD mice during early disease stage (3-4 months), THEN microglial lysosomal stress markers (LAMP1+ area, cathepsin D activity, lipid droplet count) will decrease by at least 30% compared to vehicle-treated 5xFAD controls within 4 weeks of chronic dosing.
pendingconf: 0.65
Expected outcome: At least 30% reduction in composite lysosomal stress score (LAMP1 intensity + cathepsin D activity + lipid droplet number) in entorhinal cortex and hippocampus microglia.
Falsified by: No significant reduction (<15%) in any of the three lysosomal stress markers, or a significant increase in lysosomal stress despite TREM2 agonism, indicating TREM2 lipid handling is not coupled to lysosomal stress modulation in early AD.
Method: 5xFAD transgenic mice (3 months old) treated with TREM2 agonist antibody (AL002c, 10mg/kg, i.p., bi-weekly) vs. age-matched vehicle controls, with stereological quantification of microglial lysosomal parameters at 4 weeks post-treatment (n≥12 per group).
IF microglia are exposed to a lipid-rich environment (100 μg/mL oxidized LDL) ex vivo, THEN TREM2-deficient iPSC-derived microglia will exhibit at least 50% greater lysosomal membrane permeabilization (measured by galectin-3 puncta per cell) compared to gene-corrected controls within 48 hours of treatment.
pendingconf: 0.58
Expected outcome: Galectin-3 puncta count ≥50% higher in TREM2 knockout iPSC-microglia vs. isogenic controls following oxLDL exposure, with corresponding ≥40% increase in ROS production and cathepsin B release.
Falsified by: Equivalent (<20% difference) galectin-3 puncta counts and lysosomal permeabilization markers between TREM2-deficient and control microglia, indicating lipid exposure does not engage TREM2-dependent protective pathways.
Method: iPSC-derived microglia from TREM2 knockout line vs. isogenic CRISPR-corrected control line, treated with 100 μg/mL oxLDL for 48 hours, with high-content imaging of galectin-3 puncta (n≥500 cells per condition, 3 independent differentiations).